Benzgalantamine gluconate - Generic Drug Details

What are the generic drug sources for benzgalantamine gluconate and what is the scope of patent protection?

Benzgalantamine gluconate is the generic ingredient in one branded drug marketed by Alpha Cognition and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Benzgalantamine gluconate has twenty-six patent family members in seventeen countries.

One supplier is listed for this compound.

Summary for benzgalantamine gluconate

International Patents:	26
US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for benzgalantamine gluconate
DailyMed Link:	benzgalantamine gluconate at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for benzgalantamine gluconate

Constraining patent/regulatory exclusivity:

9,763,953

Dosage:

TABLET, DELAYED RELEASE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Anatomical Therapeutic Chemical (ATC) Classes for benzgalantamine gluconate

N06DA	Anticholinesterases
N06D	ANTI-DEMENTIA DRUGS
N06	PSYCHOANALEPTICS
N	Nervous system

N06DA	Anticholinesterases
N06D	ANTI-DEMENTIA DRUGS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for benzgalantamine gluconate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-003	Jul 26, 2024		RX	Yes	No	9,763,953
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No	9,763,953
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-003	Jul 26, 2024		RX	Yes	No	11,795,176			Y
Alpha Cognition	ZUNVEYL	benzgalantamine gluconate	TABLET, DELAYED RELEASE;ORAL	218549-002	Jul 26, 2024		RX	Yes	No	11,795,176			Y

International Patents for benzgalantamine gluconate

Country	Patent Number	Title	Estimated Expiration
Japan	2024503545
Poland	1940817
Denmark	1940817
European Patent Office	4277907

Market Dynamics and Financial Trajectory for Benzgalantamine Gluconate

Last updated: February 20, 2026

What is Benzgalantamine Gluconate and its therapeutic application?

Benzgalantamine gluconate is a cholinesterase inhibitor under development for treating neurodegenerative diseases. It functions by increasing acetylcholine levels in the brain, aiming to improve cognitive function. The compound is primarily targeted at Alzheimer's disease (AD) and other dementias.

What is the current regulatory status and development pipeline?

Benzgalantamine gluconate remains in late-stage clinical trials, with no formal regulatory approval as of Q1 2023. The drug is under investigation by multiple players, including private biotech firms and large pharmaceutical companies. Key milestones include:

• Phase 3 trials initiated in 2021
• Expected NDA submission 2024
• Potential commercialization date 2025 or later

How does the market landscape for AD treatments shape the financial outlook?

The global Alzheimer's therapeutics market was valued at approximately USD 8.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5.8% to reach USD 13.3 billion by 2030 ([1]). The market comprises approved drugs like donepezil, rivastigmine, and memantine. Yet, these treatments offer symptomatic relief without halting disease progression, creating demand for disease-modifying therapies.

What is the competitive positioning of benzgalantamine gluconate?

Benzgalantamine gluconate faces competition from:

• Existing cholinesterase inhibitors
• NMDA receptor antagonists
• Emerging disease-modifying therapies (e.g., aducanumab)

Its differentiation hinges on improved efficacy, reduced side effects, and greater patient tolerability demonstrated in clinical trials. The drug's potential for real disease modification could position it as a premium product upon approval.

What are the investment and revenue projections?

Assuming approval and successful market penetration, the financial trajectory may follow:

Year	Estimated Global Sales (USD billion)	Notes
2025	0.2 – 0.3	Initial launch, limited market share
2027	0.8 – 1.2	Increasing adoption, expanded indications
2030	2.0 – 3.0	Peak sales, assuming patient access expansion

Market share estimates depend on clinical efficacy, pricing strategies, reimbursement, and competitive dynamics.

What are key factors influencing the market and financial outcomes?

• Regulatory approval: Fast track designation or priority review could accelerate launch.
• Clinical efficacy and safety: Superior outcomes over existing therapies bolster adoption.
• Pricing and reimbursement: Premium pricing possible if clinical benefits are confirmed.
• Manufacturing scalability: Ensures supply to meet demand without significant cost escalation.
• Competing pipeline innovations: Emergence of next-generation therapies could impact market share.

What risks could alter the financial trajectory?

• Delays or failures in clinical trials.
• Unfavorable safety profiles.
• Pricing constraints or reimbursement barriers.
• Competition from emerging therapies or biosimilars.
• Changes in regulatory policies.

Key Takeaways

• Benzgalantamine gluconate is in late-stage clinical development targeting Alzheimer’s disease.
• The global AD market is growing and present treatments lack disease-modifying capacity.
• Approval could lead to peak sales of USD 2-3 billion by 2030.
• Competing therapies and regulatory factors will shape financial success.
• Investment risk hinges on clinical and market validation.

FAQs

1. When might benzgalantamine gluconate reach the market?
Likely no earlier than 2024–2025, pending trial outcomes and regulatory review.

2. How does benzgalantamine plan to differentiate itself from existing treatments?
Pending trial results, potential benefits include improved efficacy, better tolerability, and disease modification.

3. What are the main competitors?
Existing cholinesterase inhibitors and NMDA receptor antagonists like donepezil and memantine, along with new therapies like anti-amyloid antibodies.

4. How sensitive is the market to regulatory delays?
Delays can push launch timelines by 1–2 years, significantly affecting revenue projections and investment returns.

5. Could reimbursement challenges limit market access?
Yes, especially if clinical benefits are marginal or if healthcare providers resist high pricing for novel therapies.

---

References

1. GlobalData. (2022). Alzheimer's Disease Therapeutics Market Size, Share & Trends. Retrieved from [URL].